{
    "root": "2f3c83a6-4d68-9759-e063-6294a90a7478",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Dexlansoprazole",
        "suffix": {
            "text": "delayed release"
        }
    },
    "value": "20250228",
    "ingredients": [
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "MAGNESIUM CARBONATE",
            "code": "0E53J927NA"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2)",
            "code": "5KY68S2577"
        },
        {
            "name": "METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)",
            "code": "74G4R6TH13"
        },
        {
            "name": "METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "DEXLANSOPRAZOLE",
            "code": "UYE4T5I70X"
        }
    ],
    "indications": "dexlansoprazole delayed-release capsules proton pump inhibitor ( ppi ) indicated patients 12 years age older : healing grades erosive esophagitis ( ee ) . ( 1.1 ) maintenance healed ee relief heartburn . ( 1.2 ) treatment symptomatic non-erosive gastroesophageal reflux disease ( gerd ) . ( 1.3 )",
    "contraindications": "recommended patients 12 years age older : full prescribing information complete dosing information dexlansoprazole delayed-release capsules indication age group adjustment patients hepatic impairment . ( 2.1 , 2.2 ) instructions ( 2.3 ) : take without regard food . swallow whole ; chew . full prescribing information alternative options .",
    "warningsAndPrecautions": "dexlansoprazole delayed-release capsules , 30 mg , opaque , blue cap light grey body , imprinted `` t001 `` black ink , capsule contains white white film-coated pellets . supplied : ndc number size 51407-746-30 bottle 30 dexlansoprazole delayed-release capsules , 60 mg , opaque , blue cap blue body , imprinted `` t002 `` black ink , capsule contains white white film-coated pellets . supplied : ndc number size 51407-747-30 bottle 30 51407-747-90 bottle 90",
    "adverseReactions": "dexlansoprazole delayed-release capsules contraindicated patients known hypersensitivity component formulation [ description ( 11 ) ] . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis urticaria [ ( 5.2 ) , ( 6 ) ] . ppis , including dexlansoprazole delayed-release capsules , contraindicated rilpivirine-containing products [ ( 7 ) ] .",
    "indications_original": "Dexlansoprazole delayed-release capsules are proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 )",
    "contraindications_original": "Recommended dosage in patients 12 years of age and older : See full prescribing information for complete dosing information for dexlansoprazole delayed-release capsules by indication and age group and dosage adjustment in patients with hepatic impairment. ( 2.1 , 2.2 ) Administration Instructions ( 2.3 ) : Take without regard to food. Swallow whole; do not chew. See full prescribing information for alternative administration options.",
    "warningsAndPrecautions_original": "Dexlansoprazole delayed-release capsules, 30 mg, are opaque, blue cap with light grey body, imprinted with \"T001\" in black ink, the capsule contains white to off white film-coated pellets. And supplied as:\n                  \n                     \n                        \n                        \n                     \n                     \n                        \n                           NDC Number\n                           Size\n                        \n                     \n                     \n                        \n                           \n                              51407-746-30\n                           \n                           \n                              Bottle of 30\n                           \n                        \n                     \n                  \n                  Dexlansoprazole delayed-release capsules, 60 mg, are opaque, blue cap with blue body, imprinted with \"T002\" in black ink, the capsule contains white to off white film-coated pellets. And supplied as:\n                  \n                     \n                        \n                        \n                     \n                     \n                        \n                           NDC Number\n                           Size\n                        \n                     \n                     \n                        \n                           51407-747-30\n                           Bottle of 30\n                        \n                        \n                           51407-747-90\n                           Bottle of 90",
    "adverseReactions_original": "Dexlansoprazole delayed-release capsules are contraindicated in patients with known hypersensitivity to any component of the formulation\n  \n   [see\n   \n    Description (11)]\n  \n   . Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis and urticaria\n  \n   [see\n   \n    Warnings and Precautions (5.2),\n   \n    Adverse Reactions (6)]\n  \n   .\n \n  \n                     PPIs, including dexlansoprazole delayed-release capsules, are contraindicated with rilpivirine-containing products\n  \n   [see\n   \n    Drug Interactions (7)]\n  \n   ."
}